EC Clinical and Medical Case Reports

E-cigarettes are becoming increasingly popular in the modern world, and although e-cigarette vapors contain fewer harmful substances compared to traditional cigarettes, some studies show that they can still cause damage to lung tissue cells. Thus, the use of electronic cigarettes is potentially harmful to the respiratory system, and the importance of developing drugs that promote a protective effect on the human bronchopulmonary system is obvious. Short peptides are one of the promising drugs that have a targeted effect on various organs and tissues. One of the peptides that restores lung function in various pathologies is the tetrapeptide ADEL, developed by Professor Vladimir Khavinson. The aim of the study was to look for substances with bronchoprotective properties that can reduce the harmful effects of electronic cigarettes and the risk of developing bronchopulmonary pathology. The results of the study showed that the AEDL peptide has a bronchoprotective and immunomodulatory effect on lung cells when exposed to e-cigarette smoke.

 Keywords: E-cigarettes; Bronchopulmonary Pathology; Short Peptides; Tetrapeptide

1. James SL, et al. “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017”. Lancet 10159 (2018): 1789-1858.
2. National Heart, Lung, and Blood Institute. “Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases”. National Institutes of Health (2012): 54.
3. Blackwell DL., et al. “Summary health statistics for U.S. adults: National Health Interview Survey, 2012”. Vital Health Statistics Series 10 260 (2014): 1-161.
4. Bloom B., et al. “Summary health statistics for U.S. children: National Health Interview Survey, 2012”. Vital Health Statistics Series 10 258 (2013): 1-81.
5. Garantziotis S and Schwartz DA. “Ecogenomics of respiratory diseases of public health significance”. Annual Review of Public Health 31 (2010): 37-51.
6. Madison MC., et al. “Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine”. Journal of Clinical Investigation 10 (2019): 4290-4304.
7. Garcia-Arcos I., et al. “Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner”. Thorax12 (2016): 1119-1129.
8. Reinikovaite V., et al. “The effects of electronic cigarette vapour on the lung: direct comparison to tobacco smoke”. European Respiratory Journal 4 (2018): 1701661.
9. Sussan TE., et al. “Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model”. PLoS One2 (2015): e0116861.
10. Crotty Alexander LE., et al. “Chronic inhalation of e-cigarette vapor containing nicotine disrupts airway barrier function and induces systemic inflammation and multiorgan fibrosis in mice”. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology6 (2018): R834-R847.
11. Wubin Xie., et al. “Association of electronic cigarette use with incident respiratory conditions among US adults from 2013 to 2018”. JAMA Network Open 11 (2020): e2020816.
12. Chun LF., et al. “Pulmonary toxicity of e-cigarettes”. American Journal of Physiology-Lung Cellular and Molecular Physiology 2 (2017): L193-L206.
13. Khavinson VK., et al. “Short peptides modulate the effect of endonucleases of wheat seedling”. Biochemistry and Biophysics Reports 437 (2011): 64-67.
14. Khavinson VK., et al. “Short cell-penetrating peptides: a model of interactions with gene promoter sites”. Bulletin of Experimental Biology and Medicine 3 (2013): 403-410.
15. Evsyukova EV., et al. “Pathogenesis, diagnosis and effective treatment of aspirin bronchial asthma with pineal peptides”. Pulmonology 6 (2003): 57-61.
16. Khavinson V Kh., et al. “Peptide substance restoring respiratory organs function”. US Patent US 7,625,870 (2009).
17. Khavinson V Kh., et al. “Peptides tissue-specifically stimulate cell differentiation during their aging”. Bulletin of Experimental Biology and Medicine 1 (2012): 148-151.
18. Khavinson V., et al. “Prospects for the use of tetrapeptide in the treatment of chronic bronchitis: molecular mechanisms”. Molecular Medicine 6 (2014): 14-20.
19. Chiappara G., et al. “The role of p21 Waf1/Cip 1 in large airway epithelium in smokers with and without COPD”. Biochimica et Biophysica Acta 10 (2013): 1473-1481.
20. Liu XH and Tang CS. “Protection against ischemia-reperfusion injury: from bench to bedside”. Zhonghua Xin Xue Guan Bing Za Zhi 8 (2006): 677-679.
21. Kamdar O., et al. “Air pollution induces enhanced mitochondrial oxidative stress in cystic fibrosis airway epithelium”. FEBS Letters 25-26 (2008): 3601-3666.
22. Porebska I., et al. “Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer”. In Vivo5 (2006): 599-004.
23. O'Nell SK., et al. “Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy”. Immunity 5 (2011): 746-756.
24. Nakken B., et al. “B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives”. Autoimmunity Reviews 1 (2011): 28-34.